CorMedix (CRMD) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CytomX Therapeutics (CTMX) has outperformed CorMedix (CRMD) over the past year, losing 23.4% versus a loss of 34.4%. Over five years, CRMD leads with a +47.1% price change compared with -50.4% for CTMX. CorMedix is the larger company by market cap ($567.4 million vs $555.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | CTMX |
|---|---|---|
| Share price | $7.28 | $2.55 |
| Market cap | $567.43M | $555.64M |
| 1-day change | 0.00% | -0.39% |
| YTD return | -37.40% | -40.14% |
| 1-year return | -34.36% | -23.42% |
| 5-year return | +47.07% | -50.39% |
| P/E ratio (TTM) | 3.55 | — |
| Forward P/E | 20.80 | — |
| EPS (TTM) | $2.05 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $8.21 |
| 52-week low | $6.13 | $2.48 |
| Distance from 52-week high | -44.09% | -68.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.58% | +380.39% |
| Average volume | 1.06M | 3.36M |
| Shares outstanding | 77.94M | 217.90M |
| Employees | 191 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTMX has outperformed CRMD by 10.9 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Healthcare · Biotechnology · 69 employees
CRMD vs CTMX FAQ
Which is bigger, CorMedix or CytomX Therapeutics?
CorMedix (CRMD) is larger, with a market capitalization of $567.43M compared with $555.64M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CRMD or CTMX?
CTMX returned -23.42% over the past 12 months, compared with -34.36% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.